Meeting
2019 ASCO Annual Meeting
Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
Authors
Paul M. Barr
University of Rochester Medical Center, Rochester, NY
Paul M. Barr , Talha Munir , Jennifer R. Brown , Susan Mary O'Brien , Jacqueline Claudia Barrientos , Nishitha M. Reddy , Steven Coutre , Constantine Si Lun Tam , Stephen P. Mulligan , Ulrich Jäger , Thomas J. Kipps , Carol Moreno , Marco Montillo , Jan Andreas Burger , John C. Byrd , Peter Hillmen , Sandra Dai , Anita Szoke , James P. Dean , Jennifer Ann Woyach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT01578707
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7510)
DOI
10.1200/JCO.2019.37.15_suppl.7510
Abstract #
7510
Poster Bd #
264
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
First Author: John C. Byrd
Poster
2016 ASCO Annual Meeting
A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE).
First Author: Clemens-Martin Wendtner
Poster
2014 ASCO Annual Meeting
DUO: A phase 3 trial of the PI3K-δ,γ inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
First Author: Ian Flinn
Poster
2013 ASCO Annual Meeting
A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.
First Author: John C. Byrd